ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans

ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

1. Fierce Biotech - Biotech 6h ago
   ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans ↗